a riskBloodborne virus from treatment abroad

Hepatitis B, hepatitis C or HIV transmitted by a reused needle, an inadequately reprocessed instrument, a contaminated injectable or an unscreened transfusion. The CDC names all three together: inadequate infection prevention and control practices place people at risk for "blood-borne infections, including hepatitis B, hepatitis C, and HIV; bloodstream infections; donor-derived infections; and surgical site infections". It asks that medical travellers be up to date on routine vaccinations, "especially hepatitis B virus immunization".

Of everything that can go wrong on a trip for treatment, this is the item with the longest delay between the exposure and the diagnosis, and the delay is what erases the link. A wound infection declares itself in days and is traced to the operation by the patient. A hepatitis C infection acquired in a clinic may be found years later on a routine liver panel, by a clinician who takes no travel history because the travel was a decade ago.

The CDC's own instruction to US facilities is the tell: obtain an explicit travel history including any medical care received abroad, and screen anyone with an overnight stay in a foreign healthcare facility in the past six months. Six months captures a resistant organism. It does not capture a virus with a long incubation.

Inference — the consequence is that this risk has no numerator anywhere. A country's hepatitis C surveillance counts cases, not the procedures that caused them, and no country attributes any share of its viral hepatitis burden to treatment its residents had abroad.

Transmission routes are the ordinary ones — injection equipment, endoscopes and dental instruments that were not reprocessed to standard, and transfused blood. Hepatitis B is preventable by vaccination before travel, and the CDC singles it out for that reason; hepatitis C is not. Post-exposure testing is only performed where somebody suspects an exposure, which requires the patient to know one happened.

As of 16 September 2026 no published figure attributes bloodborne virus infections to cross-border treatment as a class. The named quantity in this area is the blood screening one: 10 countries reporting to WHO for 2023 could not screen all donated blood for one or more of HIV, hepatitis B, hepatitis C and syphilis.